Cabozantinib Could Inhibit Hepatitis A Virus Replication in Human Hepatoma Cell Lines

Background/Objectives: Tyrosine kinase inhibitors (TKIs) have been reported to suppress the replication of several hepatotropic viruses. Despite being preventable through vaccination, hepatitis A virus (HAV) infection is still a worldwide public health issue and is also prevalent in Japan. In the context of Japan’s aging population, it is expected that the number of patients with severe hepatitis A will increase. Therefore, it is important to develop antiviral agents against HAV as therapeutic options for severe hepatitis A. Methods: In the present study, the effects of several anticancer drugs on HAV replication were examined in human hepatoma cell lines, including TKIs, which are currently used to treat patients with hepatocellular carcinoma. Results: A 48 h treatment of cabozantinib effectively inhibited HAV HA11-1299 genotype IIIA replication, and a 24 h treatment of cabozantinib with an IC50 of 3.1 µM inhibited replication of the HAV HM175-18f genotype IB subgenomic replicon. Conclusions: Cabozantinib could inhibit HAV replication in vitro and may be useful for the drug development for HAV infection.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-19
DOI
https://doi.org/10.3390/jcm15229081
Primary Topic
Hepatitis Viruses Studies and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cabozantinib Could Inhibit Hepatitis A Virus Replication in Human Hepatoma Cell Lines

Reina Sasaki, Hiroyuki Abé, Shuji Terai, Akira Sakamaki et al.
Journal of Clinical Medicine
Hepatitis Viruses Studies and Epidemiology
article

Cabozantinib Could Inhibit Hepatitis A Virus Replication in Human Hepatoma Cell Lines

Reina Sasaki, Hiroyuki Abé, Shuji Terai, Akira Sakamaki, Takeshi Yokoo, Hiroaki Okamoto, Kazunao Hayashi, Hiroteru Kamimura, Tatsuo Kanda
article en

Abstract

Background/Objectives: Tyrosine kinase inhibitors (TKIs) have been reported to suppress the replication of several hepatotropic viruses. Despite being preventable through vaccination, hepatitis A virus (HAV) infection is still a worldwide public health issue and is also prevalent in Japan. In the context of Japan’s aging population, it is expected that the number of patients with severe hepatitis A will increase. Therefore, it is important to develop antiviral agents against HAV as therapeutic options for severe hepatitis A. Methods: In the present study, the effects of several anticancer drugs on HAV replication were examined in human hepatoma cell lines, including TKIs, which are currently used to treat patients with hepatocellular carcinoma. Results: A 48 h treatment of cabozantinib effectively inhibited HAV HA11-1299 genotype IIIA replication, and a 24 h treatment of cabozantinib with an IC50 of 3.1 µM inhibited replication of the HAV HM175-18f genotype IB subgenomic replicon. Conclusions: Cabozantinib could inhibit HAV replication in vitro and may be useful for the drug development for HAV infection.

Journal of Clinical MedicineVol. 15(22)
Jichi Medical University (JP), Niigata University Medical and Dental Hospital (JP), Uonuma kikan Hospital (JP), Niigata University (JP)
Hepatitis Viruses Studies and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon